We are live on
!
Find out more
TAM
TFG Asset Management Portfolio holdings
AUM
$635M
1-Year Est. Return
28.07%
This Fund
S&P 500
This Quarter
Est. Return
-16.4%
1 Year Est. Return
+28.07%
3 Year Est. Return
+72.07%
5 Year Est. Return
+87.41%
10 Year Est. Return
+132.97%
AUM
$515M
AUM Growth
+$40.8M
(+8.6%)
Cap. Flow
+$154M
Cap. Flow
% of AUM
29.83%
Top 10 Holdings %
Top 10 Hldgs %
82.02%
Holding
40
New
12
Increased
15
Reduced
5
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
UiPath
PATH
|
+$98.8M |
| 2 |
Warner Bros
WBD
|
+$25.9M |
| 3 |
Workiva
WK
|
+$6.97M |
| 4 |
SLNO
Soleno Therapeutics
SLNO
|
+$4M |
| 5 |
Acadia Pharmaceuticals
ACAD
|
+$3.46M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RAPT
RAPT Therapeutics
RAPT
|
+$4.46M |
| 2 |
Annexon
ANNX
|
+$4.17M |
| 3 |
FOLD
Amicus Therapeutics
FOLD
|
+$3.71M |
| 4 |
Praxis Precision Medicines
PRAX
|
+$2.17M |
| 5 |
Zevra Therapeutics
ZVRA
|
+$1.72M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 62.65% |
| 2 | Healthcare | 23.94% |
| 3 | Energy | 7.28% |
| 4 | Communication Services | 4.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SLN
26
Silence Therapeutics
SLN
$642M
| $3.32M | 0.64% |
630,161
+264,792
| +72% | +$1.46M |
|
|
27
Acadia Pharmaceuticals
ACAD
$4.85B
| $3.22M | 0.63% |
+144,620
| New | +$3.46M |
|
28
Ionis Pharmaceuticals
IONS
$9.21B
| $3.14M | 0.61% |
+41,764
| New | +$3.3M |
|
|
MPLT
29
MapLight Therapeutics
MPLT
$537M
| $2.28M | 0.44% |
112,115
-52,410
| -32% | -$937K |
|
30
Relay Therapeutics
RLAY
$4.36B
| $1.81M | 0.35% |
+181,543
| New | +$1.62M |
|
31
Snowflake
SNOW
$116B
| $1.51M | 0.29% |
10,000
| – | – |
|
|
AARD
32
Aardvark Therapeutics
AARD
$139M
| $1.19M | 0.23% |
+316,621
| New | +$3.28M |
|
|
TECX
33
Tectonic Therapeutic
TECX
$652M
| $1.16M | 0.23% |
+37,588
| New | +$925K |
|
34
Ultragenyx Pharmaceutical
RARE
$2.56B
| $827K | 0.16% |
+39,473
| New | +$889K |
|
35
Karyopharm Therapeutics
KPTI
$44.9M
| $295K | 0.06% |
+52,984
| New | +$404K |
|
|
36
CALL
Karyopharm Therapeutics
KPTI
$44.9M
| $279K | 0.05% |
+50,000
| New | +$381K |
|
|
AVDL
37
DELISTED
Avadel Pharmaceuticals
AVDL
| – | – |
-43,763
| Closed | -$943K |
|
|
FOLD
38
DELISTED
Amicus Therapeutics
FOLD
| – | – |
-260,771
| Closed | -$3.71M |
|
|
RAPT
39
DELISTED
RAPT Therapeutics
RAPT
| – | – |
-131,770
| Closed | -$4.46M |
|
|
40
Zevra Therapeutics
ZVRA
$649M
| – | – |
-192,518
| Closed | -$1.72M |
|
Similar funds
AP
WCM
FTC
KCM
EIM
PCM
BI
KCMH
TFG Asset Management's Q1 2026 Portfolio in Review
As of Q1 2026, TFG Asset Management held 40 positions worth $515M, up 8.6% from $474M the previous quarter. Its ten largest holdings account for 82% of the portfolio.
TFG Asset Management deployed $154M of net new capital in Q1 2026, opening 12 new positions and adding to 15 existing holdings. Its largest new stake was Warner Bros: 923,725 shares worth $25.4M.
By sector, the portfolio is most concentrated in Technology at 63% of assets, down from 71% a quarter earlier, followed by Healthcare and Energy.
On the sell side, the largest reduction was Annexon, an estimated $4.17M trimmed.
- TFG Asset Management's largest Q1 2026 buy was Warner Bros: 923,725 shares worth $25.4M.
- TFG Asset Management added most to UiPath in Q1 2026, an estimated $98.8M increase.
- TFG Asset Management's biggest Q1 2026 reduction was Annexon, cutting an estimated $4.17M.
- TFG Asset Management fully exited RAPT Therapeutics in Q1 2026, selling an estimated $4.46M.
- TFG Asset Management's ten largest holdings make up 82% of its $515M portfolio in Q1 2026.
- TFG Asset Management opened 12 new positions and closed 4 in Q1 2026.
- TFG Asset Management's portfolio value rose 8.6% quarter-over-quarter to $515M.
Based on TFG Asset Management's 13F filing for Q1 2026, filed 15 May 2026.